Correlation Between Molecular Partners and AN2 Therapeutics

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and AN2 Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and AN2 Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and AN2 Therapeutics, you can compare the effects of market volatilities on Molecular Partners and AN2 Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of AN2 Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and AN2 Therapeutics.

Diversification Opportunities for Molecular Partners and AN2 Therapeutics

0.24

Correlation Coefficient

Molecular Partners  AN2 Therapeutics

Modest diversification

The 3 months correlation between Molecular and AN2 is 0.24. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and AN2 Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AN2 Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with AN2 Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AN2 Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and AN2 Therapeutics go up and down completely randomly.

Pair Corralation between Molecular Partners and AN2 Therapeutics

Given the investment horizon of 90 days Molecular Partners AG is expected to generate 1.16 times more return on investment than AN2 Therapeutics. However, Molecular Partners is 1.16 times more volatile than AN2 Therapeutics. It trades about 0.08 of its potential returns per unit of risk. AN2 Therapeutics is currently generating about 0.03 per unit of risk. If you would invest  362.00  in Molecular Partners AG on August 31, 2024 and sell it today you would earn a total of  220.00  from holding Molecular Partners AG or generate 60.77% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Molecular Partners AG  vs.  AN2 Therapeutics

Molecular Partners

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point.

AN2 Therapeutics

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in AN2 Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, AN2 Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Molecular Partners and AN2 Therapeutics

The main advantage of trading using opposite Molecular Partners and AN2 Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, AN2 Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AN2 Therapeutics will offset losses from the drop in AN2 Therapeutics' long position.

The idea behind Molecular Partners AG and AN2 Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.